Diagnostica Stago Inc.

Diagnostica Stago Inc., a foreign-owned manufacturer headquartered in Parsippany, New Jersey, operates as a prime contractor supplying hemostasis and thrombosis testing equipment, reagents, analyzers, and maintenance services to federal healthcare agencies through GSA Schedule 66-III (Critical Analyzers, Laboratory Equipment and Supplies) and single-award blanket purchase agreements. The company does not hold SBA socioeconomic certifications and competes on full-and-open procurements without set-aside status, having maintained federal contractor registration since 2001.

Diagnostica Stago's federal footprint concentrates on coagulation diagnostic products and services delivered to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks and the Defense Health Agency. Recent representative work includes a $215,000 BPA with VISN 17 for cost-per-reportable-result coagulation testing (August 2026), a $1.3 million Defense Health Agency BPA for diagnostic supplies and reagents extending through March 2030, a $500,000 VISN 9 BPA covering cost-per-reportable-result patient testing and equipment lease services across Tennessee and Kentucky facilities (May 2026), a $3.6 million VISN 6 BPA for coagulation testing equipment and supplies through September 2029 (October 2024), and a $904,696 VISN 4 BPA for coagulation analyzers and supplies through November 2026 (September 2025). The company also supplied $267,339.96 in coagulation assays to the Defense Health Agency (May 2026) and $664,401.68 in STA R Max and Compact Max instruments and consumables for Madigan Army Medical Center (October 2025).

Customer concentration is pronounced and stable. Five agencies account for 24 percent of awards by count: VISN 16 (309 awards, $35.2 million), Army Medical Command (242 awards, $21.3 million), VISN 4 (210 awards, $27.5 million), Navy Bureau of Medicine and Surgery (169 awards, $12.3 million), and VISN 20 (152 awards, $21.5 million). By dollar value, the top five shift slightly: VISN 12 anchors the ranking with 50 awards worth $82.2 million, followed by VISN 9 (137 awards, $55.2 million), VISN 16 (309 awards, $35.2 million), Defense Health Agency (76 awards, $34.2 million), and VISN 4 (210 awards, $27.5 million). Together these five agencies represent approximately 50 percent of combined potential value. The company's federal customer base spans 51 distinct agencies, but Veterans Affairs and Defense Health Agency relationships dominate by concentration.

Diagnostica Stago holds position on multiple vehicle types anchored by GSA Schedule 66-III, which carries 2,171 task orders valued at $327 million combined potential value—the overwhelming majority of the vendor's federal activity. The company also maintains active ordering under Federal Supply Schedule V797P6696A (1,095 task orders, $37 million), Federal Supply Schedule V797P5564X (233 task orders, $1.4 million), and multiple single-award blanket purchase agreements with individual VISNs and the Defense Health Agency, each carrying ceiling values between $120 thousand and $3.6 million and extending through 2029 or 2030.

Award volume has remained steady: 90 awards in 2022, declining to 71 in 2025 and 40 through October 2026. Over 4,560 total awards span the source period, with $467.3 million in combined potential value and $164.5 million in obligated dollars (35 percent drawdown). Fifty-two awards face ultimate completion within the next twenty-four months, carrying combined potential value of $10.3 million and triggering recompete risk for the vendor and opportunity for competitors. The company's category concentration reflects its core business: Analytical Laboratory Instrument Manufacturing (1,640 awards), In-Vitro Diagnostic Substance Manufacturing (462 awards), and Surgical and Medical Instrument Manufacturing (276 awards) dominate the award distribution. PSC-level concentration centers on Laboratory Equipment and Supplies (1,550 awards) and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (846 awards).

Diagnostica Stago subcontracts minimally in the visible record; a single sub-award appeared under Battelle Memorial Institute in January 2022 for coagulation testing work on a weapons of mass destruction civil support team project. The vendor operates predominantly as a direct prime contractor, with no named teaming relationships or notable subcontractor engagements in the source award history. The company's federal sales strategy relies on direct procurement from end-user federal medical facilities and healthcare networks through established GSA Schedule pricing and pre-competed blanket purchase agreements, enabling rapid task ordering without additional competition.